Characterize Pulmonary Endarterectomy-Eligible Patients Enrolled in a U.S. Managed Care Plan

Characterize Pulmonary Endarterectomy-Eligible Patients Enrolled in a U.S. Managed Care Plan

March 2014, Vol 145, No. 3_MeetingAbstracts Pulmonary Vascular Disease | March 2014 Characterize Pulmonary Endarterectomy-Eligible Patients Enrolled ...

124KB Sizes 0 Downloads 13 Views

March 2014, Vol 145, No. 3_MeetingAbstracts Pulmonary Vascular Disease | March 2014

Characterize Pulmonary Endarterectomy-Eligible Patients Enrolled in a U.S. Managed Care Plan Vijay Joish, PhD; David Muccino, MD; Naresh Rao, MS Bayer HealthCare Pharmaceuticals, Wayne, NJ

Chest. 2014;145(3_MeetingAbstracts):531A. doi:10.1378/chest.1808781

Abstract SESSION TITLE: DVT/PE Posters SESSION TYPE: Poster Presentations PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM PURPOSE: The objective of this study was to describe demographic and clinical characteristics of PEA-eligible patients including the cost and length of stay related to the surgery. METHODS: Data for this study came from two large managed care claims databases. Surgery-eligible CTEPH patients were identified based on the surgical procedure codes for PEA of 33916 or 38.15 anytime during January 1, 2007 through June 30, 2011. The date of the PEA surgery served as the index date. All baseline demographic characteristics, resource use, and costs were extracted in the twelve months leading to and six months post the index event and separately for the surgery itself. Demographic variables were extracted at a patient level from administrative files. Disease-related variables including cost and length of stay (LOS) related to PEA were ascertained from medical claims. RESULTS: 46 patients were identified that underwent PEA. The average age of the sample was 52 years (+17.4), 50% females, with the majority in the south (35%) and west (26%) region of the country. Based on the international classification of diseases, the top five documented circulatory conditions in this sample were acute pulmonary heart disease (78%), pulmonary embolism and infarction (78%), other heart disease (74%), chronic pulmonary heart disease (67%), and other chronic pulmonary heart disease (61%). Prior to PEA, 9% were on a phosphodiesterase

inhibitor, 7% on endothelial receptor antagonist, and 4% on prostacyclin analogue. The average total cost of PEA, $124,899 (+212,817.8) for a total mean of 13 days (+ 13.3) of inpatient stay. The average cost was greatest in North Central (n=7, $172,106, LOS=9.0) and lowest in West (n=12, $86,892, LOS=10.3) region of the country. CONCLUSIONS: This is the first study that characterizes patients undergoing PEA using real-world data. CLINICAL IMPLICATIONS: Pulmonary endarterectomy (PEA) is a curative procedure for eligible patients with chronic thromboembolic pulmonary hypertension (CTEPH), a type of pulmonary hypertension (PH). This study highlights demographic characteristics, background treatment, and co-existing conditions among CTEPH patients that are surgery eligible. DISCLOSURE: Vijay Joish: Employee: employee of Bayer healthcare David Muccino: Employee: Employee of Bayer Healthcare Naresh Rao: Consultant fee, speaker bureau, advisory committee, etc.: contract researcher paid by Bayer healthcare No Product/Research Disclosure Information